Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Nanopore Technologies Regulatory News (ONT)

Share Price Information for Oxford Nanopore Technologies (ONT)

Share Price is delayed by 15 minutes
Get Live Data
120.20    1.30 (1.09%)
Bid:
119.60
Ask:
120.10
Spread: 0.50 (0.418%)
Market Cap: £1.17b
ONT Live PriceLast checked at - London Stock Exchange

Intraday Oxford Nanopore Technologies Share Chart

PDMR Notification (ESPP) and Director Declaration

1 Nov 2021 18:30

RNS Number : 9858Q
Oxford Nanopore Technologies plc
01 November 2021
 

1 November 2021

Oxford Nanopore Technologies plc (the "Company")

Employee Stock Purchase Plan PDMR Notification and Director Declaration

The Company announces that on 1 November 2021 it has granted options under its US Employee Stock Purchase Plan ("ESPP") including to James (Spike) Willcocks, a Person Discharging Managerial Responsibilities ("PDMR") of the Company. The ESPP is an all-employee scheme operated for the Company's US employees. The options granted under the ESPP are, subject to the ESPP rules, exercisable at the end of a 14-month saving plan, which will end on 1 January 2023. This announcement is made pursuant to the Company's obligations under Article 19(3) of the UK Market Abuse Regulation.

The Company further announces that, in accordance with Listing Rule 9.6.14, Adrian Hennah has been appointed as Non-Executive Director of Unilever plc with effect from 1 November 2021.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

James (Spike) Willcocks - grant of options under ESPP

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

James Willcocks

2

Reason for the notification

a)

Position/status

Chief Strategy Officer

b)

Initial/Amendment notification

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Oxford Nanopore Technologies plc

b)

LEI

213800IRWQ2Q6M2CDW55

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

 

Identification code

 Employee Stock Purchase Plan options over Ordinary shares with a nominal value of £0.0001 each

 

GB00BP6S8Z30

b)

Nature of the transaction

Grant of options under Employee Stock Purchase Plan

c)

Price

 

Volume

 

Total

460p

 

2,378

 

£10,938.80

d)

Aggregated Price

 

Aggregated volume

 

Aggregated Total

N/A

 

N/A

 

N/A

e)

Date of the transaction

1 November 2021

f)

Place of the transaction

London Stock Exchange (XLON)

 

For further information please contact:

Oxford Nanopore Technologies plc

media@nanoporetech.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEAPFFEFKFFFA
Date   Source Headline
24th Aug 20227:00 amRNSNotice of Results
11th Aug 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Aug 20225:30 pmRNSIssue of Equity and Total Voting Rights
12th Jul 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
11th Jul 20227:00 amRNSSale and leaseback of headquarters building
1st Jul 20225:16 pmRNSIssue of Equity and Total Voting Rights
30th Jun 20227:15 amRNSDuncan Tatton-Brown appointed as Non-Exec Chair
23rd Jun 20224:30 pmRNSResult of AGM
13th Jun 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Jun 20224:00 pmRNSIssue of Equity and Total Voting Rights
31st May 20226:30 pmRNSDirector/PDMR Shareholding
26th May 20227:00 amRNSONT releases Remora:most comprehensive methylation
20th May 20227:00 amRNSOxford Nanopore announces tech updates
19th May 20229:06 amRNSONT opens user conference, rich science programme
13th May 20227:00 amRNSONT chosen for comprehensive human genome program
11th May 20224:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
3rd May 20224:00 pmRNSIssue of Equity and Total Voting Rights
12th Apr 20226:15 pmRNSShare Incentive Plan - Director/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:01 pmRNSDirector/PDMR Shareholding
12th Apr 20221:00 pmRNSDirector/PDMR Shareholding
12th Apr 20227:00 amRNSPublication of Annual Report and Notice of AGM
6th Apr 20221:00 pmRNSBlock listing Interim Review
5th Apr 202211:00 amRNSDirector/PDMR Shareholding
4th Apr 20222:00 pmRNSGenomics England expands Nanopore use in cancer
1st Apr 20225:00 pmRNSIssue of Equity and Total Voting Rights
1st Apr 20227:00 amRNSAgreement
30th Mar 20222:00 pmRNSONT shows new high-accuracy, high-output chemistry
24th Mar 20227:00 amRNSNanopore sequencing profiles TB: FIND evaluation
23rd Mar 20222:02 pmRNSOxford Nanopore releases Short Fragment Mode
22nd Mar 20227:00 amRNSPreliminary Results and Guidance Update
11th Mar 20225:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
10th Mar 202212:30 pmRNSHolding(s) in Company
8th Mar 20227:03 amRNSPublication: Nanopore IDs >50 genetic diseases
1st Mar 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Feb 20227:00 amRNSNotice of Results
11th Feb 20225:30 pmRNSShare Incentive Plan - Director/PDMR Shareholding
1st Feb 20225:00 pmRNSIssue of Equity and Total Voting Rights
24th Jan 20223:00 pmRNSAppointment of Senior Independent Director
18th Jan 20221:00 pmRNSHolding(s) in Company
13th Jan 20227:00 amRNSFastest human genome sequence uses Oxford Nanopore
11th Jan 20226:00 pmRNSShare Incentive Plan - Director/PDMR Shareholding
7th Jan 202212:00 pmRNSUpdate to FY21 revenue guidance
7th Jan 20227:00 amRNSCompany to present at JP Morgan Healthcare conf
4th Jan 20226:30 pmRNSIssue of Equity and Total Voting Rights
20th Dec 20215:00 pmRNSHolding(s) in Company
13th Dec 20216:15 pmRNSShare Incentive Plan - Director/PDMR Shareholding
2nd Dec 20217:00 amRNSOxford Nanopore announces technology updates
1st Dec 20217:00 amRNSIssue of Equity and Total Voting Rights
9th Nov 20217:03 amRNSUpdate to revenue guidance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.